Feedback / Questions
D3S-001 - D3 Bio
https://www.prnewswire.com/news-releases/d3-bio-inc-announces-fda-breakthrough-therapy-designation-and-orphan-drug-designation-for-d3s-001-for-the-treatment-of-patients-with-kras-g12c-mutated-cancers-302540808.html
Aug 28, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next